SCHEMBL15834863

SCHEMBL15834863

CCOC(=O)[C@H](Cc1ccc(COc2ccccc2)c(OCc2ccccc2)c1)NC(=O)NCc1ccc(NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.48
▸ TDP1 Q9NUW8 4/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ ATM Q13315 2/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ PSMB1 P20618 4/20 0.43
▸ PSMB9 P28065 3/20 0.43
▸ PSMB5 P28074 3/20 0.43
▸ PSMB10 P40306 3/20 0.43
▸ PSMB2 P49721 3/20 0.43
▸ PSMB8 P28062 2/20 0.43
▸ PPARG P37231 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ KLKB1 P03952 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ LTA4H P09960 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2053665 0.91 MAPT (0.51) MAPTTDP1KDM4EATML3MBTL1
SCHEMBL12643655 0.91 MAPT (0.51) MAPTTDP1KDM4EATML3MBTL1
SCHEMBL14576371 0.91 MAPT (0.51) MAPTTDP1KDM4EATML3MBTL1
SCHEMBL15832199 0.87 ATM (0.57) MAPTATML3MBTL1NPC1RAB9A
SCHEMBL15834851 0.87 PTPN1 (0.52) PSMB1PSMB9PSMB5PSMB10PSMB2
SCHEMBL15832201 0.86 PPID (0.52) MAPTATML3MBTL1NPC1RAB9A
SCHEMBL12643860 0.86 MAPT (0.56) MAPTTDP1KDM4EATML3MBTL1
SCHEMBL15834853 0.80 MAPT (0.53) MAPTTDP1KDM4EATML3MBTL1
SCHEMBL14644454 0.78 SCN9A (0.47) PPARGPTPN1SCN9A
SCHEMBL15832202 0.78 LMNA (0.48) L3MBTL1PPARGLTA4HALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179687-A1 New Inhibitors of Cyclophilins and Uses Thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179687-A1 New Inhibitors of Cyclophilins and Uses Thereof FKBP3, FKBP4, FKBP5 MAPT 3890/4885TDP1 4285/4885KDM4E 3906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback